Login Register Cart 0
Generic placeholder image

Current Cardiology Reviews

Editor-in-Chief

ISSN (Print): 1573-403X
ISSN (Online): 1875-6557

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Sacubitril/Valsartan: A New Dawn has Begun! A Revisited Review

Author(s): Mahmoud Abdelnabi *, Yehia Saleh , Abdallah Almaghraby, Hany Girgis and Fady Gerges

Volume 18, Issue 3, 2022

Published on: 24 November, 2021

Article ID: e310821195982 Pages: 11

DOI: 10.2174/1573403X17666210831142452

Price: $65

Abstract

Heart Failure (HF) is among the major causes of global morbidity as well as mortality. Increased prevalence, frequent and prolonged hospitalization, rehospitalization, long-term consumption of healthcare resources, absenteeism, and death upsurge the economic burden linked to HF. For decades, Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Blockers (ARBs), Beta-Blockers (BBs), and mineralocorticoid receptor antagonists (MRA), have remained the mainstay of the standard of care for HF management. Despite their proven efficacy and cost-effectiveness, HF remains a global pandemic and is still increasing in prevalence. Sacubitril/ Valsartan (SAC/VAL) is an Angiotensin Receptor/Neprilysin Inhibitor (ARNI) that proved out to be a game-changer drug in HF treatment. Recent data indicated that SAC/VAL is more efficient and can improve the overall quality of life of HF patients with reduced ejection fraction (HFrEF) with fewer side effects. It is now incorporated in the guidelines as an alternative to ACEIs or ARBs to lower morbidity in addition to mortality in HFrEF patients. This review article will discuss the current guidelines-approved indications and highlight the potential emerging indications, in addition to the currently ongoing clinical trials that will expand the use of SAC/VAL.

Keywords: Sacubitril/valsartan, heart failure with reduced ejection fraction (HFrEF), PARADIGM-HF, heart failure with preserved ejection fraction (HFpEF), ventricular arrhythmias, remodeling.

Graphical Abstract

[1]
Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325(5): 293-302.
[http://dx.doi.org/10.1056/NEJM199108013250501] [PMID: 2057034]
[2]
Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344(22): 1651-8.
[http://dx.doi.org/10.1056/NEJM200105313442201] [PMID: 11386263]
[3]
Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364(1): 11-21.
[http://dx.doi.org/10.1056/NEJMoa1009492] [PMID: 21073363]
[4]
Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics-2019 update: A report from the american heart association. Circulation 2019; 139(10): e56-e528.
[http://dx.doi.org/10.1161/CIR.0000000000000659] [PMID: 30700139]
[5]
Gu J, Noe A, Chandra P, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol 2010; 50(4): 401-14.
[http://dx.doi.org/10.1177/0091270009343932] [PMID: 19934029]
[6]
Oefner C, Roques BP, Fournie-Zaluski M-C, Dale GE. Structural analysis of neprilysin with various specific and potent inhibitors. Acta Crystallogr D Biol Crystallogr 2004; 60(Pt 2): 392-6.
[http://dx.doi.org/10.1107/S0907444903027410] [PMID: 14747736]
[7]
McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371(11): 993-1004.
[http://dx.doi.org/10.1056/NEJMoa1409077] [PMID: 25176015]
[8]
Senni M, McMurray JJ, Wachter R, et al. Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. Eur J Heart Fail 2016; 18(9): 1193-202.
[http://dx.doi.org/10.1002/ejhf.548] [PMID: 27170530]
[9]
Senni M, McMurray JJV, Wachter R, et al. Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study. Eur J Heart Fail 2018; 20(3): 491-500.
[http://dx.doi.org/10.1002/ejhf.1054] [PMID: 29164797]
[10]
Liu RC. Focused treatment of heart failure with reduced ejection fraction using sacubitril/valsartan. Am J Cardiovasc Drugs 2018; 18(6): 473-82.
[http://dx.doi.org/10.1007/s40256-018-0280-5] [PMID: 29850980]
[11]
Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37(27): 2129-200.
[http://dx.doi.org/10.1093/eurheartj/ehw128] [PMID: 27206819]
[12]
Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: A report of the american college of cardiology/american heart association task force on clinical practice guidelines and the heart failure society of america. J Am Coll Cardiol 2017; 70(6): 776-803.
[http://dx.doi.org/10.1016/j.jacc.2017.04.025] [PMID: 28461007]
[13]
Ezekowitz JA, O’Meara E, McDonald MA, et al. 2017 Comprehensive update of the Canadian Cardiovascular Society guidelines for the management of heart failure. Can J Cardiol 2017; 33(11): 1342-433.
[http://dx.doi.org/10.1016/j.cjca.2017.08.022] [PMID: 29111106]
[14]
Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002; 106(8): 920-6.
[http://dx.doi.org/10.1161/01.CIR.0000029801.86489.50] [PMID: 12186794]
[15]
Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med 2019; 380(6): 539-48.
[http://dx.doi.org/10.1056/NEJMoa1812851] [PMID: 30415601]
[16]
Wachter R, Senni M, Belohlavek J, et al. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. Eur J Heart Fail 2019; 21(8): 998-1007.
[http://dx.doi.org/10.1002/ejhf.1498] [PMID: 31134724]
[17]
Greene SJ, Fonarow GC, Vaduganathan M, Khan SS, Butler J, Gheorghiade M. The vulnerable phase after hospitalization for heart failure. Nat Rev Cardiol 2015; 12(4): 200-9.
[18]
Marti CN, Fonarow GC, Gheorghiade M, Butler J. Timing and duration of interventions in clinical trials for patients with hospitalized heart failure. Circ Heart Fail 2013; 6(5): 1095-101.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.113.000518] [PMID: 24046476]
[19]
Crespo-Leiro MG, Anker SD, Maggioni AP, et al. European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. Eur J Heart Fail 2016; 18(6): 613-25.
[http://dx.doi.org/10.1002/ejhf.566] [PMID: 27324686]
[20]
Kociol RD, Liang L, Hernandez AF, Curtis LH, Heidenreich PA, Yancy CW. Are we targeting the right metric for heart failure? Comparison of hospital 30-day readmission rates and total episode of care inpatient days. Ame Heart J 2013; 165(6): 987-4.
[21]
Kociol RD, Hammill BG, Fonarow GC, et al. Generalizability and longitudinal outcomes of a national heart failure clinical registry: Comparison of Acute Decompensated Heart Failure National Registry (ADHERE) and non-ADHERE Medicare beneficiaries. Am Heart J 2010; 160(5): 885-92.
[http://dx.doi.org/10.1016/j.ahj.2010.07.020] [PMID: 21095276]
[22]
Solomon SD, Dobson J, Pocock S, et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 2007; 116(13): 1482-7.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.107.696906] [PMID: 17724259]
[23]
Iborra-Egea O, Gálvez-Montón C, Roura S, et al. Mechanisms of action of sacubitril/valsartan on cardiac remodeling: a systems biology approach. NPJ Syst Biol Appl 2017; 3(1): 12.
[http://dx.doi.org/10.1038/s41540-017-0013-4] [PMID: 28649439]
[24]
Almufleh A, Marbach J, Chih S, et al. Ejection fraction improvement and reverse remodeling achieved with Sacubitril/Valsartan in heart failure with reduced ejection fraction patients. Am J Cardiovasc Dis 2017; 7(6): 108-13.
[PMID: 29348971]
[25]
Martens P, Beliën H, Dupont M, Vandervoort P, Mullens W. The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction. Cardiovasc Ther 2018; 36(4): e12435.
[http://dx.doi.org/10.1111/1755-5922.12435] [PMID: 29771478]
[26]
De Diego C, Gonzalez-Torres L, Centurion E, Macias M, De Lara G. P303 Effects of angiotensin-neprilysin inhibition as compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable de. EP Europace 2018; 20(Suppl. 1): i44-.
[http://dx.doi.org/10.1093/europace/euy015.115]
[27]
Martens P, Nuyens D, Rivero-Ayerza M, et al. Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction. Clin Res Cardiol 2019; 108(10): 1074-82.
[http://dx.doi.org/10.1007/s00392-019-01440-y] [PMID: 30788621]
[28]
Zacà V. Sacubitril/valsartan or an implantable cardioverter-defibrillator in heart failure with reduced ejection fraction patients: a cost-effectiveness analysis. J Cardiovasc Med (Hagerstown) 2018; 19(10): 597-605.
[http://dx.doi.org/10.2459/JCM.0000000000000708] [PMID: 30160656]
[29]
Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol 2014; 11(9): 507-15.
[http://dx.doi.org/10.1038/nrcardio.2014.83] [PMID: 24958077]
[30]
Henning RJ. Diagnosis and treatment of heart failure with preserved left ventricular ejection fraction. World J Cardiol 2020; 12(1): 7-25.
[http://dx.doi.org/10.4330/wjc.v12.i1.7] [PMID: 31984124]
[31]
Biering-Sorensen T, Shah A, Claggett B, et al. The Angiotensin receptor neprilysin inhibitor (arni), sacubitril/valsartan, improves left ventricular myocardial deformation in heart failure with preserved ejection fraction (paramount trial). J Am Coll Cardiol 2018; 71(11)(Suppl.): A2665.
[http://dx.doi.org/10.1016/S0735-1097(18)33206-6]
[32]
Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012; 380(9851): 1387-95.
[http://dx.doi.org/10.1016/S0140-6736(12)61227-6] [PMID: 22932717]
[33]
Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 2019; 381(17): 1609-20.
[http://dx.doi.org/10.1056/NEJMoa1908655] [PMID: 31475794]
[34]
Kang D-H, Park S-J, Shin S-H, et al. Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation: PRIME study. Circulation 2019; 139(11): 1354-65.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.118.037077] [PMID: 30586756]
[35]
Rossi A, Dini FL, Faggiano P, et al. Independent prognostic value of functional mitral regurgitation in patients with heart failure. A quantitative analysis of 1256 patients with ischaemic and non-ischaemic dilated cardiomyopathy. Heart 2011; 97(20): 1675-80.
[http://dx.doi.org/10.1136/hrt.2011.225789] [PMID: 21807656]
[36]
Asgar AW, Mack MJ, Stone GW. Secondary mitral regurgitation in heart failure: pathophysiology, prognosis, and therapeutic considerations. J Am Coll Cardiol 2015; 65(12): 1231-48.
[http://dx.doi.org/10.1016/j.jacc.2015.02.009] [PMID: 25814231]
[37]
Agricola E, Ielasi A, Oppizzi M, et al. Long-term prognosis of medically treated patients with functional mitral regurgitation and left ventricular dysfunction. Eur J Heart Fail 2009; 11(6): 581-7.
[http://dx.doi.org/10.1093/eurjhf/hfp051] [PMID: 19398488]
[38]
Grigioni F, Detaint D, Avierinos J-F, Scott C, Tajik J, Enriquez-Sarano M. Contribution of ischemic mitral regurgitation to congestive heart failure after myocardial infarction. J Am Coll Cardiol 2005; 45(2): 260-7.
[http://dx.doi.org/10.1016/j.jacc.2004.10.030] [PMID: 15653025]
[39]
Desai AS, Solomon SD, Shah AM, et al. Effect of sacubitril-valsartan vs. enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 2019; 322(11): 1077-84.
[http://dx.doi.org/10.1001/jama.2019.12843] [PMID: 31475296]
[40]
Torrado J, Cain C, Mauro AG, et al. Sacubitril/valsartan averts adverse post-infarction ventricular remodeling and preserves systolic function in rabbits. J Am Coll Cardiol 2018; 72(19): 2342-56.
[http://dx.doi.org/10.1016/j.jacc.2018.07.102] [PMID: 30384891]
[41]
American College of Cardiology 2021 LCZ696 in Advanced Heart Failure - American College of Cardiology 2021. Available from: https://www.acc.org/latest-in-cardiology/clinical-trials/2021/05/14/19/47/life
[42]
A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients. 2019. Available from: https://clinicaltrials.gov/ct2/show/NCT03066804
[43]
de Castro RL, de Alcantara Lima N, da Costa Lino DO, Melgar TA. A rare case of non-prosthetic aortic valve infectious endocarditis caused by Achromobacter xylosoxidans. Am J Case Rep 2020; 21.
[44]
Shaddy R, Canter C, Halnon N, et al. Design for the sacubitril/valsartan (LCZ696) compared with enalapril study of pediatric patients with heart failure due to systemic left ventricle systolic dysfunction (PANORAMA-HF study). Am Heart J 2017; 193: 23-34.
[http://dx.doi.org/10.1016/j.ahj.2017.07.006] [PMID: 29129252]
[45]
Sacubitril-valsartan and Heart Failure Patients : The ENTRESTO-SAS study 2019. Available from: https://clinicaltrials.gov/ct2/show/NCT02916160
[46]
The effects of sacubitril/valsartan on the heart functions 2019. Available from: https://clinicaltrials.gov/ct2/show/NCT03830814
[47]
Prospective ARNI vs. ACE Inhibitor trial to determine superiority in reducing heart failure events after MI. 2019. Available from: https://clinicaltrials.gov/ct2/show/NCT02924727
[48]
The effects of sacubitril/valsartan compared to valsartan on LV remodelling in asymptomatic LV systolic dysfunction after MI 2019. Available from: https://clinicaltrials.gov/ct2/show/NCT03552575
[49]
Abdelnabi M, Almaghraby A. The role of sacubitril/valsartan in post-acute myocardial infarction 2019. Available from: https://clinicaltrials.gov/ct2/show/NCT03893435
[50]
Pulmonary artery pressure reduction with ENTresto (Sacubitril/Valsartan) 2019. Available from: https://clinicaltrials.gov/ct2/show/NCT02788656
[51]
Study of efficacy of oral sacubitril/valsartan in adult patients with non-obstructive hypertrophic cardiomyopathy. 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT04164732
[52]
Tafelmeier M, Baessler A, Wagner S, et al. Design of the SILICOFCM study: Effect of sacubitril/valsartan vs. lifestyle intervention on functional capacity in patients with hypertrophic cardiomyopathy. Clin Cardiol 2020; 43(5): 430-40.
[http://dx.doi.org/10.1002/clc.23346] [PMID: 32125709]

Rights & Permissions Print Cite
Article Metrics
29
1
© 2024 Bentham Science Publishers | Privacy Policy